Page 32 - Read Online

Felton et al. J Cancer Metastasis Treat 2018;4:51 I http://dx.doi.org/10.20517/2394-4722.2018.39 Page 9 of 9

2006;8:193-201.
4. Azzoni C, Bottarelli L, Campanini N, Di Cola G, Bader G, Mazzeo A, Salvemini C, Morari S, Di Mauro D, Donadei E, Roncoroni L, Bordi
C, Sarli L. Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the
tumorigenesis. Int J Colorectal Dis 2007;22:115-26.
5. Watanabe T, Kobunai T, Toda E, Yamamoto Y, Kanazawa T, Kazama Y, Tanaka J, Tanaka T, Konishi T, Okayama Y, Sugimoto Y, Oka T,
Sasaki S, Muto T, Nagawa H. Distal colorectal cancers with microsatellite instability (MSI) display distinct gene expression profiles that are
different from proximal MSI cancers. Cancer Res 2006;66:9804-8.
6. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H, Group CRCPTS. Comparison of 17,641 patients with right- and left-sided
colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010;53:57-64.
7. Wang C, Wainberg ZA, Raldow A, Lee P. Differences in cancer-specific mortality of right- versus left-sided colon adenocarcinoma: a sur-
veillance, epidemiology, and end results database analysis. JCO Clinical Cancer Informatics 2017;1:1-9.
8. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers?
Ann Surg Oncol 2008;15:2388-94.
9. Weiss JM, Pfau PR, O’Connor ES, King J, LoConte N, Kennedy G, Smith MA. Mortality by stage for right- versus left-sided colon cancer:
analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol 2011;29:4401-9.
10. Lim DR, Kuk JK, Kim T, Shin EJ. Comparison of oncological outcomes of right-sided colon cancer versus left-sided colon cancer after cu-
rative resection: which side is better outcome? Medicine (Baltimore) 2017;96:e8241.
11. Polakis P. The oncogenic activation of beta-catenin. Curr Opin Genet Dev 1999;9:15-21.
12. Terracina KP, Aoyagi T, Huang WC, Nagahashi M, Yamada A, Aoki K, Takabe K. Development of a metastatic murine colon cancer model.
J Surg Res 2015;199:106-14.
13. Golovko D, Kedrin D, Yilmaz Ö, Roper J. Colorectal cancer models for novel drug discovery. Expert Opin Drug Discov 2015;10:1217-29.
14. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø. Twelve colorectal cancer cell lines exhibit highly variable growth
and metastatic capacities in an orthotopic model in nude mice. Eur J Cancer 2004;40:1593-8.
15. Cheng K, Metry M, Felton J, Shang AC, Drachenberg CB, Xu S, Zhan M, Schumacher J, Guo GL, Polli JE, Raufman JP. Diminished gall-
bladder filling, increased fecal bile acids, and promotion of colon epithelial cell proliferation and neoplasia in fibroblast growth factor 15-de-
ficient mice. Oncotarget 2018;9:25572-85.
16. Cheng K, Xie G, Khurana S, Heath J, Drachenberg CB, Timmons J, Shah N, Raufman JP. Divergent effects of muscarinic receptor subtype
gene ablation on murine colon tumorigenesis reveals association of M3R and zinc finger protein 277 expression in colon neoplasia. Mol
Cancer 2014;13:77.
17. Raufman JP, Shant J, Xie G, Cheng K, Gao XM, Shiu B, Shah N, Drachenberg CB, Heath J, Wess J, Khurana S. Muscarinic receptor
subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice. Carcinogenesis
2011;32:1396-402.
18. Raufman JP, Dawson PA, Rao A, Drachenberg CB, Heath J, Shang AC, Hu S, Zhan M, Polli JE, Cheng K. Slc10a2-null mice uncover colon
cancer-promoting actions of endogenous fecal bile acids. Carcinogenesis 2015;36:1193-200.
19. Raufman JP, Samimi R, Shah N, Khurana S, Shant J, Drachenberg C, Xie G, Wess J, Cheng K. Genetic ablation of M3 muscarinic receptors
attenuates murine colon epithelial cell proliferation and neoplasia. Cancer Res 2008;68:3573-8.
20. Dougherty U, Cerasi D, Taylor I, Kocherginsky M, Tekin U, Badal S, Aluri L, Sehdev A, Cerda S, Mustafi R, Delgado J, Joseph L, Zhu H,
Hart J, Threadgill D, Fichera A, Bissonnette M. Epidermal growth factor receptor is required for colonic tumor promotion by dietary fat in
the azoxymethane/dextran sulfate sodium model: roles of transforming growth factor-{alpha} and PTGS2. Clin Cancer Res 2009;15:6780-
9.
21. Boivin GP, Washington K, Yang K, Ward JM, Pretlow TP, Russell R, Besselsen DG, Godfrey VL, Doetschman T, Dove WF, Pitot HC,
Halberg RB, Itzkowitz SH, Groden J, Coffey RJ. Pathology of mouse models of intestinal cancer: consensus report and recommendations.
Gastroenterology 2003;124:762-77.
22. Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del Pulgar MT, Sancho FJ, Nistal M, Lacal JC, Mangues R. Or-
thotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol
2007;170:1077-85.
23. Hackl C, Man S, Francia G, Milsom C, Xu P, Kerbel RS. Metronomic oral topotecan prolongs survival and reduces liver metastasis in im-
proved preclinical orthotopic and adjuvant therapy colon cancer models. Gut 2013;62:259-71.
24. Hite N, Klinger A, Hellmers L, Maresh GA, Miller PE, Zhang X, Li L, Margolin DA. An optimal orthotopic mouse model for human
colorectal cancer primary tumor growth and spontaneous metastasis. Dis Colon Rectum 2018;61:698-705.
25. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz HJ. Understanding the role of primary tumour localisation in colorectal cancer treatment
and outcomes. Eur J Cancer 2017;84:69-80.
26. Leijssen LGJ, Dinaux AM, Kunitake H, Bordeianou LG, Berger DL. Pathologic factors are more important than tumor location in long-term
survival in colon cancer. Int J Colorectal Dis 2018;33:709-17.
27. Kopp R, Lambrecht G, Mutschler E, Moser U, Tacke R, Pfeiffer A. Human HT-29 colon carcinoma cells contain muscarinic M3 receptors
coupled to phosphoinositide metabolism. Eur J Pharmacol 1989;172:397-405.
28. Belo A, Cheng K, Chahdi A, Shant J, Xie G, Khurana S, Raufman JP. Muscarinic receptor agonists stimulate human colon cancer cell mi-
gration and invasion. Am J Physiol Gastrointest Liver Physiol 2011;300:G749-60.
29. Raufman JP, Cheng K, Saxena N, Chahdi A, Belo A, Khurana S, Xie G. Muscarinic receptor agonists stimulate matrix metalloproteinase
1-dependent invasion of human colon cancer cells. Biochem Biophys Res Commun 2011;415:319-24.
30. Sanmamed MF, Chester C, Melero I, Kohrt H. Defining the optimal murine models to investigate immune checkpoint blockers and their
combination with other immunotherapies. Ann Oncol 2016;27:1190-8.